FIELD: medicine.
SUBSTANCE: invention refers to medicine and describes pharmaceutical compositions in the form of a capsule consisting of granules containing a therapeutic agent in the form of a homogenous mixture with at least one pharmaceutically acceptable excipient wherein said therapeutic agent means pyrimidylaminobenzamide agent as 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide (nilotinib) or its pharmaceutically acceptable salt, preferentially wherein said nilotinib is hydrochloride monohydrate, and whereon said granule additionally means a surfactant wherein the surfactant concentration additionally means 0 to 1% at weight of said pharmaceutical composition, and wherein said pharmaceutical composition contains a lubricant does not exceed 1% at weight of said pharmaceutical composition. What is also described is a method for preparing pharmaceutical compositions.
EFFECT: compositions provide bioavailability of the therapeutic agents in the oral introduction.
12 cl, 2 ex, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATING PROLIFERATIVE DISORDERS AND OTHER PATHOLOGICAL CONDITIONS MEDIATED BY ACTIVITY OF KINASE BCR-ABL, C-KIT, DDR1, DDR2 OR PDGF-R | 2010 |
|
RU2625835C2 |
| PHARMACEUTICAL COMPOSITIONS CONTAINING S1P RECEPTOR MODULATOR | 2007 |
|
RU2487703C2 |
| NOVEL COMPOSITION | 2006 |
|
RU2483716C2 |
| NEW COMPOSITION | 2006 |
|
RU2821230C2 |
| METHOD FOR TREATING METABOLISM DISORDERS MAINLY DIABETES CASES AND DISEASES OR STATES RELATED TO DIABETES | 2000 |
|
RU2280447C2 |
| ORGANIC COMPOUNDS | 2004 |
|
RU2358716C2 |
| ORAL PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475237C2 |
| METHOD FOR PREPARING PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2475236C2 |
| SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING COMBINATION OF VILDAGLIPTIN AND GLIQUIDONE | 2014 |
|
RU2585378C1 |
| DERIVATIVES OF 2-AMINONICOTINE AMIDE AND THEIR USING AS INHIBITORS OF TYROSINE KINASE VEGF RECEPTORS | 2001 |
|
RU2296124C2 |
